In a historic achievement, esteemed breast cancer researchers Professor Jane Visvader and Professor Geoff Lindeman from the Walter and Eliza Hall Institute of Medical Research (WEHI) have been awarded the prestigious Buchanan Medal by the Royal Society, the United Kingdom’s national science academy. This marks only the third time an Australian recipient has received the medal since its inception in 1897, and notably, Visvader and Lindeman are the first joint winners in the award’s history.
A Legacy of Groundbreaking Research
Professors Visvader and Lindeman, who have led WEHI’s breast cancer research program since its establishment in 1998, have been at the forefront of pioneering discoveries that have significantly advanced the understanding and treatment of breast cancer. Their work has laid the foundation for new prevention strategies and therapeutic approaches, with some of their findings now being tested in clinical trials.
Their research has been particularly influential in identifying the source cells of cancer in women with a high risk of breast cancer due to mutations in the BRCA1 and BRCA2 genes. This work has not only contributed to the scientific community’s understanding of cancer development but also provided new avenues for prevention, including the international breast cancer prevention study (BRCA-P).
Recognition of a Collaborative Effort
Receiving the Buchanan Medal is a testament to the decades of dedication and collaboration between Visvader, Lindeman, and their team. Professor Visvader expressed her gratitude for the recognition, emphasizing the collective effort involved in their research.
“While we are honored to receive this award, it really acknowledges the incredible team of scientists, colleagues, and patient advocates we’ve worked with over the past 25 years,” said Professor Visvader. “This recognition highlights the progress we’ve made, but also the critical need for continued support for fundamental research, which is essential for improving outcomes for future generations.”
Professor Lindeman echoed these sentiments, noting that their research has already informed new treatments and prevention strategies for women at high risk of breast cancer. He expressed optimism about the future, as emerging technologies and new drug developments promise to further personalize and enhance breast cancer therapies.
Unraveling the Mysteries of Breast Cancer
Breast cancer remains a significant health challenge, with over 20,000 new cases diagnosed annually in Australia and more than 3,100 deaths each year. While most breast cancers arise spontaneously, about 5% are hereditary, linked to mutations in the BRCA1 and BRCA2 genes. Women with these mutations face a significantly higher risk of developing aggressive breast and ovarian cancers, often leading to preventative surgeries such as mastectomies.
Professors Visvader and Lindeman’s work has been pivotal in identifying the specific cells that give rise to breast cancer in high-risk women. Their discovery of breast stem cells in 2006 was a breakthrough that opened new pathways for understanding different types of breast cancer and how they could be controlled. Further research identified that the ‘daughter’ progenitor cells of these stem cells are likely the cells-of-origin for breast cancer in women with BRCA1 mutations.
The duo’s findings have significantly impacted the scientific community’s approach to breast cancer prevention and treatment, particularly for those at high genetic risk.
Celebrating a Lifelong Commitment to Science
The recognition from the Royal Society, the world’s longest-standing scientific academy, is a fitting tribute to the pair’s contributions to biomedical science. WEHI Director Professor Ken Smith praised their collaborative and innovative approach to research, predicting that their partnership will continue to yield important insights for years to come.
“Professors Visvader and Lindeman have made extraordinary contributions to the field of breast cancer research, uncovering critical pathways for prevention and treatment,” said Professor Smith. “Their work exemplifies the power of collaboration and creativity in science, and I’m confident their legacy will continue to shape the future of cancer research.”
In addition to the Buchanan Medal, both Professors Visvader and Lindeman have received numerous accolades throughout their careers. Professor Visvader is a Fellow of the Royal Society, the Australian Academy of Science, the Australian Academy of Health and Medical Sciences, and the American Association of Cancer Research Academy. Professor Lindeman is also a Fellow of the Australian Academy of Science and the Australian Academy of Health and Medical Sciences.
The Buchanan Medal will be formally presented to Professors Visvader and Lindeman at a ceremony in London on November 29, 2024.